PlasmaBound raises funding to accelerate bonding technology adaptation
23 Jan 2023
Pictured left to right at NovaUCD are PlasmaBound founders, Dr James Nicholas Barry, Alan Barry and Xavier Montibert. Photo Credit: PlasmaBound
Irish startup PlasmaBound (Dublin) secured a €750,000 investment from Business Venture Partners (BVP) in December 2022, in addition to previous funding from Act Venture Capital, Atlantic Bridge and Enterprise Ireland. This brings total funding to €3.1 million, which will be used to advance PlasmaBound’s vision to make lightweight composite materials affordable for low- to mid-range vehicles.
PlasmaBound has developed controlled polymer ablation (CPA), an environmentally friendly, high-speed and low-cost bonding technology for composite materials. The company anticipates that its technology will help move the drive toward lower CO2 emissions and longer electric vehicle (EV) range into mass-market applications.
PlasmaBound, a University College Dublin (UCD) spin-out company, was co-founded in 2017 by Dr. James Nicholas Barry, Alan Barry and Xavier Montibert. It was recently selected as one of five startups to win access to the Hyundai Motor Co. and KIA Corp. sponsored 2022 Accelerate the Future Challenge. PlasmaBound is headquartered at NovaUCD.
“We are delighted to have secured this investment from BVP. It will help PlasmaBound bring about a further positive impact to the environment with the adaption of our CPA technology in manufacturing process throughout various sectors, with a particular focus on automotive, aerospace and space, along with consumer electronics, and sports and eisure,” Alan Barry, CEO, PlasmaBound, says.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.